Early trial tests drug for debilitating nerve damage in rare heart condition
Disease control
Ongoing
This small, early-phase study is testing whether the drug patisiran can help control nerve damage in people with wild-type ATTR amyloidosis, a rare condition where abnormal proteins build up in the body. Ten participants with nerve symptoms will receive patisiran infusions every …
Phase: EARLY_PHASE1 • Sponsor: Austin Neuromuscular Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC